Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AGA’s Amplatzer for headaches

This article was originally published in The Gray Sheet

Executive Summary

AGA Medical begins a 120-patient, multi-center, randomized trial of its Amplatzer patent foramen ovale occluder device to reduce the number and severity of migraines. Patient enrollment in the PFO closure Reduction In Migraine with Aura (PRIMA) trial commenced May 3 to examine the connections between certain types of migraines and heart defects affecting 20% of adults, the firm says. PRIMA differs from previous PFO migraine trials, such as NMT Medical's MIST I, in that the endpoint is 50% reduction of migraines in 50% of patients, AGA says. MIST I failed to meet its primary endpoint of complete migraine cessation (1"The Gray Sheet" April 17, 2006, p. 9)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023508

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel